Status and phase
Conditions
Treatments
About
To confirm the tolerability and safety of combined administration of ONO-4059 and R-MPV therapy in untreated PCNSL patients.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
20 participants in 1 patient group
Loading...
Central trial contact
Ono Pharmaceutical Co., Ltd.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal